{"id":"W3095584460","doi":"10.1136/annrheumdis-2020-eular.529","title":"OP0225 TOFACITINIB AS MONOTHERAPY FOLLOWING METHOTREXATE WITHDRAWAL IN PATIENTS WITH PSORIATIC ARTHRITIS PREVIOUSLY TREATED WITH OPEN-LABEL TOFACITINIB + METHOTREXATE: A RANDOMISED, PLACEBO-CONTROLLED SUBSTUDY OF OPAL BALANCE","year":2020,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Autoimmune and Inflammatory Disorders Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"Pfizer (Canada); University of Toronto","funders":"Celgene; Gilead Sciences; Pfizer; Amgen","keywords":"Tofacitinib; Medicine; Placebo; Psoriatic arthritis; Internal medicine; Methotrexate; Clinical endpoint; Gastroenterology; Arthritis; Randomized controlled trial; Surgery; Rheumatoid arthritis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000888265,0.0004793039,0.002547477,0.000162241,0.0001297356,0.00007380745,0.0007124341,0.00008125143,0.0002492118],"category_scores_gemma":[0.001516722,0.0002843542,0.0003368363,0.000845744,0.0002459547,0.000402257,0.0001544627,0.000252145,0.000008264564],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002444041,"about_ca_system_score_gemma":0.0005166677,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002879071,"about_ca_topic_score_gemma":0.00002273924,"domain_scores_codex":[0.9955575,0.0009157301,0.001367415,0.0005128147,0.001070125,0.0005764058],"domain_scores_gemma":[0.9971038,0.0006240848,0.0009048304,0.0007169838,0.0003487204,0.0003016401],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5055349,0.005553924,0.4242494,0.001472898,0.006451836,0.00009864991,0.005574369,0.0003499099,0.0002183321,0.0001145374,0.0004600725,0.04992123],"study_design_scores_gemma":[0.8036312,0.006699686,0.1723507,0.007705975,0.001141681,0.000007176101,0.00166152,0.002826039,0.00285584,0.0002424643,0.00009838718,0.0007792639],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9877402,0.002705775,0.00005178436,0.000831781,0.00002369934,0.007931859,0.0001017481,0.00004331169,0.0005698527],"genre_scores_gemma":[0.997426,0.0006305085,0.0004113435,0.000514199,0.000008111506,0.0007036555,0.00007023627,0.00007470467,0.0001612126],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2980964,"threshold_uncertainty_score":0.9999608,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03334244674960742,"score_gpt":0.3189558147628077,"score_spread":0.2856133680132003,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}